Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Rani Therapeutics Holdings, Inc.

Market Cap 75.87M 65.53M 60.38M 56.52M 106M 7.21B 108M 713M 278M 3.51B 285M 279M 12.15B P/E Ratio 2026 *
-3.93x
P/E Ratio 2027 * -3.46x
Enterprise Value 75.87M 65.53M 60.38M 56.52M 106M 7.21B 108M 713M 278M 3.51B 285M 279M 12.15B EV / Sales 2026 *
18.4x
EV / Sales 2027 * 15.4x
Free-Float
78.28%
Yield 2026 *
-
Yield 2027 * -
1 day-5.22%
1 week-8.37%
Current month-20.06%
1 month-31.52%
3 months-42.42%
6 months-43.28%
Current year-43.70%
1 week 0.76
Extreme 0.76
0.85
1 month 0.76
Extreme 0.76
1.12
Current year 0.68
Extreme 0.68
1.54
1 year 0.39
Extreme 0.387
3.87
3 years 0.39
Extreme 0.387
8.75
5 years 0.39
Extreme 0.387
36.27
10 years 0.39
Extreme 0.387
36.27
Manager TitleAgeSince
Chief Executive Officer 45 2021-05-31
Director of Finance/CFO 56 2021-04-05
Chief Tech/Sci/R&D Officer 42 2021-12-31
Director TitleAgeSince
Chairman 69 2021-05-31
Director/Board Member 80 2018-08-31
Director/Board Member 69 2021-04-05
Date Insider Type Main position Quantity % Market Cap.
06-02Free

Executive/Senior Manager

805,500 0.8077%
06-02Free

Chief Technology Officer

805,500 0.8077%
06-02Free

Founder

3,800,000 3.8106%
Change 5-day change 1-year change 3-year change Capi.($)
-5.22%-8.37%+44.70%-83.93% 75.87M
-2.58%+0.03%+58.02%+111.59% 56.42B
+2.72%+3.26%+46.05%+47.37% 44.54B
+1.12%+2.79%-15.04%-18.40% 22.9B
+1.17%+3.85%-0.89%+407.26% 21.21B
-0.32%+1.97%+16.91%-34.50% 16.4B
+0.12%+0.47%+9.77%-38.34% 15.4B
-0.69%+0.82%+27.75%+182.91% 13.35B
+0.96%+9.74%+17.55% - 12.36B
+1.61%+1.28%+95.75%+206.59% 11.15B
Average -0.11%+1.04%+30.06%+86.73% 21.38B
Weighted average by Cap. +0.20%+2.36%+32.96%+100.31%

Financials

2026 *2027 *
Net sales 4.13M 3.56M 3.29M 3.07M 5.76M 392M 5.85M 38.79M 15.12M 191M 15.49M 15.16M 661M 4.92M 4.25M 3.92M 3.67M 6.88M 468M 6.98M 46.28M 18.05M 228M 18.48M 18.09M 789M
Net income -33.21M -28.69M -26.43M -24.74M -46.37M -3.16B -47.09M -312M -122M -1.54B -125M -122M -5.32B -39.93M -34.49M -31.78M -29.75M -55.75M -3.8B -56.61M -375M -146M -1.85B -150M -147M -6.4B
Net Debt - -
Logo Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Employees
70
Date Price Change Volume
26-06-12 0.7601 $ -5.22% 910,010
26-06-11 0.8020 $ +2.43% 564,224
26-06-10 0.7830 $ -3.48% 572,501
26-06-09 0.8112 $ -3.38% 1,232,347
26-06-08 0.8396 $ +1.22% 488,414
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.7601USD
Average target price
7.500USD
Spread / Average Target
+886.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RANI Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!